OSE-CYTOMASK®, a new CIS-Demasking 1 cytokine bispecific technology. CLEC-1, a novel immune checkpoint target. NANTES, France - April 3, 2025, 6:00 p.m. CET - OSE Immunotherapeutics SA (ISIN: ...

OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025 OSE-CYTOMASK®, a new CIS-Demasking 1 cytokine bispecific technology. CLEC-1, a novel immune ...

Advancement of AbbVie Inc. and OSE Immunotherapeutics strategic partnership to develop ABBV-230: in April 2024, the Hart-Scott-Rodino waiting period expired enabling teams to commence work around the ...